- Brand Name : Hepcdac
- Composition : Daclatasvir Dihydrochloride
- Manufactured by : Cipla Ltd.
- Strength : 60 mg
- Form : Tablets
- Packing : Pack of 28 Tablets
Cipla Ltd, a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients, is the manufacturer of Hepcdac 60 mg Tablets. Hepcdac is a generic version of Daklinza (Daclatasvir). It is an antiviral medication which is used to treat genotype 1 and genotype 3 chronic hepatitis C in adults with or without cirrhosis. This medication works by lowering a load of hepatitis C virus in the body and removing the virus from the blood over a period of time.
Hepcdac Daclatasvir must be used in combination with other hepatitis C medications and is not effective if taken alone. Results from clinical studies as well as preliminary real-life data regarding the combination of Sofosbuvir (a nucleotide polymerase inhibitor) and Daclatasvir, a first-in-class NS5A replication complex inhibitor, demonstrate that it is one of the most promising antiviral therapies, with once-daily oral dosing, a low pill burden, good tolerability, and limited drug–drug interactions, in addition to high antiviral potency, with >90% sustained virologic response rates.
For over 5 years, Drugssquare has become one of the most respected pharmaceutical names in India as well as across more than 150 countries. Our portfolio includes 1500 plus products across therapeutic categories with one quality standard globally. We constantly strive to provide safe, cost effective healthcare to improve the standard of living in the Philippines and the many international markets in which we serve. Our aim throughout is customer satisfaction, achieved through our core values : Quality, Affordability, Customer Care, Choice, Accessibility, Partnership and Responsibility.
Our mission statement –
“making quality healthcare an affordable and accessible reality throughout the world, has been the cornerstone of our success.“